AbbVie Exec Says Co Expects A Step Down In Humira Revenue In 2025
Portfolio Pulse from Benzinga Newsdesk
Abbvie executive announced that the company expects a decline in Humira revenue in 2025.
June 12, 2024 | 2:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Abbvie expects a decline in Humira revenue in 2025, which could impact the company's overall financial performance.
Humira is a significant product for Abbvie, and a decline in its revenue could negatively impact the company's financials. Investors may react negatively to this news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100